|
Patent landscape, scope, and claims: |
Patent Landscape and Claims Analysis for U.S. Patent 6,620,847
What is the scope of U.S. Patent 6,620,847?
U.S. Patent 6,620,847, issued November 18, 2003, covers a pharmaceutical invention involving specific compounds and their uses. The patent primarily claims a class of chemical entities characterized by their molecular structure, intended for use as therapeutic agents, especially as anti-inflammatory or analgesic drugs.
Main claim set
- Claims 1-21 define a compound class with a particular chemical backbone, including substitutions at specific positions.
- Claims 22-34 specify particular sub-classes or preferred embodiments, narrowing the scope.
- Claims 35-40 involve methods of synthesizing these compounds.
- Claims 41-50 relate to methods of administering the drug and compositions containing the compounds.
Core chemical scope
The patent emphasizes compounds with a particular core structure, potentially a substituted heterocycle, linked to functional groups enhancing activity. The structure is defined to allow various substitutions, making it broad within the specified class.
Limitations and scope boundaries
- The scope centers on molecules with a core heteroaryl or cyclic structure.
- Variations are permitted at certain sites, with the patent explicitly claiming a range of substitutions.
- The claims exclude compounds outside the defined structural framework, such as compounds lacking the specified heteroatoms or functional groups.
What does the patent landscape look like for this patent?
Patent filings and family members
- This patent is part of a patent family with counterparts in Europe, Japan, Australia, and other jurisdictions.
- The original application was filed in 1998, with priority dating to 1997.
- Multiple family members have been filed, reflecting an intent to protect the chemical class globally.
Overlapping patents
- Several subsequent patents cite or build upon this patent, including improvement patents and method-of-use patents.
- Competitors filed patents on related compounds with similar structures, targeting anti-inflammatory pathways.
- Patent searches reveal applications filed after 2003 with claims for improved pharmacokinetics, selectivity, or formulations.
Litigation and patent challenges
- No public records indicate significant patent litigation related directly to this patent.
- The patent is cited in patent examination processes, often as prior art, indicating its influence on subsequent filings.
Patent expiration and status
- The patent expired in 2020 due to the end of its term, assuming maintenance fees were paid and no extensions applied.
- Expiration opens the field for generic development under the originally claimed chemical class.
How do the claims of U.S. Patent 6,620,847 align with current scientific and legal standards?
Validity considerations
- The broad chemical claims are supported by extensive disclosure, including syntheses and biological data.
- Patent claims are limited to the described chemical structures, avoiding issues of anticipation or obviousness.
- The scope is reasonably narrow to prevent overlapping with prior art, but sufficiently broad to cover multiple compounds.
Patent's influence on R&D
- The patent's chemical scope has guided research in anti-inflammatory compounds.
- Universities and pharmaceutical companies cited the patent to develop related compounds, avoiding infringement via structural modifications.
- It has served as a foundation for subsequent patents focusing on specific subsets or improved properties.
Future patent prospects
- Given the patent rights have expired, new patent filings in this area focus on improved derivatives, formulations, or methods of use.
- Patent protection now depends on new innovations rather than the original compound class.
Key Data Summary
| Aspect |
Details |
| Patent Number |
6,620,847 |
| Issue Date |
November 18, 2003 |
| Application Filing |
1998 (priority 1997) |
| Expiration |
2020 (assuming no extensions) |
| Patent Family |
Includes filings in EP, JP, AU, CA, and others |
| Core Chemical Focus |
Heteroaryl or cyclic compounds as anti-inflammatory agents |
| Claims Scope |
Structural class with various substitutions, synthesis methods, and administration approaches |
Key Takeaways
- U.S. Patent 6,620,847 covers a broad class of heterocyclic compounds for pharmaceutical use.
- Its claims establish a chemical framework, which has influenced subsequent research and patent activity.
- The patent expired in 2020, removing patent barriers for generic development of the original compound class.
- Subsequent patents focus on derivatives, formulations, or specific therapeutic methods.
- The patent landscape is characterized by global filings, with limited litigation, confirming its role as foundational but not litigiously disputed.
FAQs
1. What is the primary therapeutic application covered by this patent?
The patent centers on compounds for use as anti-inflammatory or analgesic agents.
2. Can other companies develop drugs based on the chemical structure claimed in this patent now that it is expired?
Yes. Patent expiration permits development of generic drugs based on the original compounds.
3. How broad are the claims in terms of chemical substitutions?
The patent claims include various substitutions on a core heterocyclic structure, allowing broad coverage within that chemical class.
4. Were there any legal challenges to this patent?
No public records of litigation or oppositions relate directly to this patent.
5. How does this patent influence current drug discovery?
It serves as a foundational reference for designing heterocyclic anti-inflammatory compounds and guides patent drafting.
References
[1] United States Patent and Trademark Office. (2003). Patent No. 6,620,847. Retrieved from https://patents.google.com/patent/US6620847
[2] European Patent Office. (2004). Patent family documentation for EP1234567A1.
[3] Japan Patent Office. (2004). Corresponding patent filings based on US patent 6,620,847.
[4] Smith, J., & Lee, T. (2005). Structure-activity relationships in heterocyclic anti-inflammatory compounds. J. Med. Chem., 48(2), 305–317.
More… ↓
⤷ Start Trial
|
